Dr. Guru Sonpavde, GU Oncology, Phase I Director, Christopher K. Glanz Chair Bladder Cancer Research, Prof. UCF - AdventHealth Central Florida
Publisher |
Becker's Healthcare
Media Type |
audio
Publication Date |
Dec 10, 2023
Episode Duration |
00:15:48

This episode features Dr. Guru Sonpavde, GU Oncology, Phase I Director, Christopher K. Glanz Chair Bladder Cancer Research, Prof. UCF - AdventHealth Central Florida. Here, he discusses his recent NEJM paper on a Phase 3 trial tied to GU cancer and the drug combo of chemotherapy and immunotherapy improving durable complete remission rates to ~22% from ~12%, most focused on and excited about in the next 3-5 years, advice for evolving researchers, and more.

Link to paper here: https://www.nejm.org/doi/full/10.1056/NEJMoa2309863

This episode features Dr. Guru Sonpavde, GU Oncology, Phase I Director, Christopher K. Glanz Chair Bladder Cancer Research, Prof. UCF - AdventHealth Central Florida. Here, he discusses his recent NEJM paper on a Phase 3 trial tied to GU cancer and the drug combo of chemotherapy and immunotherapy improving durable complete remission rates to ~22% from ~12%, most focused on and excited about in the next 3-5 years, advice for evolving researchers, and more.Link to paper here: https://www.nejm.org/doi/full/10.1056/NEJMoa2309863 (https://www.nejm.org/doi/full/10.1056/NEJMoa2309863)

This episode features Dr. Guru Sonpavde, GU Oncology, Phase I Director, Christopher K. Glanz Chair Bladder Cancer Research, Prof. UCF - AdventHealth Central Florida. Here, he discusses his recent NEJM paper on a Phase 3 trial tied to GU cancer and the drug combo of chemotherapy and immunotherapy improving durable complete remission rates to ~22% from ~12%, most focused on and excited about in the next 3-5 years, advice for evolving researchers, and more.

Link to paper here: https://www.nejm.org/doi/full/10.1056/NEJMoa2309863

This episode currently has no reviews.

Submit Review
This episode could use a review!

This episode could use a review! Have anything to say about it? Share your thoughts using the button below.

Submit Review